DDInter1166 DDInter1676
Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a number of unique characteristics that have led to its increased use in the last two decades; in particular, methadone has a lower risk of neuropsychiatric toxicity compared to other opioids (due to a lack of active metabolites), minimal accumulation in renal failure, good bioavailability, low cost, and a long duration of action.[F4685,F4688,F4691,A185885,A185900,A185903] Due to its unique mechanism of action, methadone is particularly useful for the management of hard to treat pain syndromes
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Methadone {u} (Compound) resembles {v} (Compound) Diphenoxylate
Methadone {u} (Compound) resembles {v} (Compound) Ethopropazine
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Methadone {u} (Compound) binds {v} (Gene) CYP2B6
Methadone {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Methadone {u} (Compound) causes {v} (Side Effect) Cardiomyopathy
Methadone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ammonium chloride
Methadone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Peginterferon alfa-2a
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Methadone {u} may lead to a major life threatening interaction when taken with {v} Naltrexone
Methadone (Compound) resembles Diphenoxylate (Compound)
Methadone (Compound) resembles Ethopropazine (Compound)
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Trospium
Methadone (Compound) binds CYP2B6 (Gene)
Methadone (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Methadone (Compound) causes Cardiomyopathy (Side Effect)
Methadone may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride
Methadone may cause a minor interaction that can limit clinical effects when taken with Peginterferon alfa-2a
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Methadone may lead to a major life threatening interaction when taken with Naltrexone